Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells.

Breast cancer research and treatment - 1 Apr 2015

Krishnan Samaya R, Nair Binoj C, Sareddy Gangadhara R, Roy Sudipa Saha, Natarajan Mohan, Suzuki Takayoshi, Peng Yan, Raj Ganesh, Vadlamudi Ratna K

Abstract excerpt

Triple-negative breast cancer (TNBC), the most aggressive breast cancer subtype, occurs in younger women and is associated with poor prognosis. Gain-of-function mutations in TP53 are a frequent occurrence in TNBC and have been demonstrated to repress apoptosis and up-regulate cell cycle progression. Even though TNBC responds to initial chemotherapy, resistance to chemotherapy develops and is a major clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Apoptosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Co-Repressor Proteins

Share to Drug Resistance, Neoplasm

Share to E2F1 Transcription Factor

Share to Gene Knockdown Techniques

Share to Triple Negative Breast Neoplasms

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 25788226
DOI: 10.1007/s10549-015-3339-x
PMCID: PMC4385448

Genes

PELP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells.PMID 25788226Read ↗

PRMT1 regulates EGFR and Wnt signaling pathways and is a promising target for combinatorial treatment of breast cancerSemantic proximity Read ↗

BRCA1-Associated Epigenetic Regulation of p73 Mediates an Effector Pathway for Chemosensitivity in Ovarian CarcinomaSemantic proximity Read ↗

TP53 Mutations in Breast and Ovarian Cancer.Semantic proximity Read ↗

Targeting the Heterogeneous Genomic Landscape in Triple-Negative Breast Cancer through Inhibitors of the Transcriptional MachinerySemantic proximity Read ↗

TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers.Semantic proximity Read ↗

CENPF Knockdown Inhibits Adriamycin Chemoresistance In Triple Negative Breast Cancer Mediated By Rb-E2F1 AxisSemantic proximity Read ↗

Mutant p53 cooperates with ETS2 to promote etoposide resistance.Semantic proximity Read ↗

Overexpression of PKMYT1 associated with poor prognosis and immune infiltration may serve as a target in triple-negative breast cancerSemantic proximity Read ↗

Death effector domain-containing protein induces vulnerability to cell cycle inhibition in triple-negative breast cancerSemantic proximity Read ↗

TP53R175H mutation promotes breast cancer cell proliferation through CORO1A-P38 MAPK pathway regulation.Semantic proximity Read ↗

p53, BRCA1 and breast Cancer chemoresistance.Semantic proximity Read ↗

Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.